Designer drugs: the biologic therapies

被引：0
作者：
Johnston, Sarah [1 ]
机构：
[1] Southmead Gen Hosp, Dept Immunol & Immunogenet, Bristol BS10 5NB, Avon, England
来源：
CLINICAL MEDICINE | 2006年 / 6卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：337 / 343
页数：7
相关论文
共 27 条
  • [1] A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
    Bathon, JM
    Martin, RW
    Fleischmann, RM
    Tesser, JR
    Schiff, MH
    Keystone, EC
    Genovese, MC
    Wasko, MC
    Moreland, LW
    Weaver, AL
    Markenson, J
    Finck, BK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) : 1586 - 1593
  • [2] Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody.
    Beniaminovitz, A
    Itescu, S
    Lietz, K
    Donovan, M
    Burke, EM
    Groff, BD
    Edwards, N
    Mancini, DM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (09) : 613 - 619
  • [3] Systemic vasculitis: Still a challenging disease
    Buhaescu, I
    Covic, A
    Levy, J
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 46 (02) : 173 - 185
  • [4] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY
    CALIFF, RM
    SHADOFF, N
    VALETT, N
    BATES, E
    GALEANA, A
    KNOPF, W
    SHAFTEL, J
    BENDER, MJ
    AVERSANO, T
    RAQUENO, J
    GURBEL, P
    COWFER, J
    COHEN, M
    CROSS, P
    BITTL, J
    EDDINGS, K
    TAYLOR, M
    DEROSA, K
    HATTEL, L
    COOPER, L
    ESHELMAN, B
    FINTEL, D
    NIEMYSKI, P
    KLEIN, L
    KENNEDY, H
    THORNTON, T
    KEREIAKES, D
    MARTIN, L
    ANDERSON, L
    HIGBY, N
    ELLIS, S
    BREZINA, K
    GEORGE, B
    CHAPEKIS, A
    SMITH, D
    ANWAR, A
    GERBER, TL
    PRITCHARD, GL
    MYLER, R
    SHAW, R
    MURPHY, M
    WARD, K
    MADIGAN, NP
    BLANKENSHIP, J
    HALBERT, M
    FLANAGAN, C
    TANNENBAUM, M
    POLICH, M
    STEVENSON, C
    TCHENG, J
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) : 956 - 961
  • [5] Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
    Edwards, JCW
    Szczepanski, L
    Szechinski, J
    Filipowicz-Sosnowska, A
    Emery, P
    Close, DR
    Stevens, RM
    Shaw, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (25) : 2572 - 2581
  • [6] Treatment of ulcerative colitis with a humanized antibody to the α4β7 integrin
    Feagan, BG
    Greenberg, GR
    Wild, G
    Fedorak, RN
    Paré, P
    McDonald, JWD
    Dubé, R
    Cohen, A
    Steinhart, AH
    Landau, S
    Aguzzi, RA
    Fox, IH
    Vandervoort, MK
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (24) : 2499 - 2507
  • [7] Abatacept for rheumatoid arthritis refractory to tumor necrosis factor α inhibition
    Genovese, MC
    Becker, J
    Schiff, M
    Luggen, M
    Sherrer, Y
    Kremer, J
    Birbara, C
    Box, J
    Natarajan, K
    Nuamah, I
    Li, T
    Aranda, R
    Hagerty, DT
    Dougados, M
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (11) : 1114 - 1123
  • [8] BSR Biologics Registry
    Griffiths, I
    Silman, A
    Symmons, D
    Scott, DGI
    [J]. RHEUMATOLOGY, 2004, 43 (12) : 1463 - 1464
  • [9] Brief report - Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis
    Kleinschmidt-DeMasters, BK
    Tyler, KL
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (04) : 369 - 374
  • [10] CONTINUOUS CULTURES OF FUSED CELLS SECRETING ANTIBODY OF PREDEFINED SPECIFICITY
    KOHLER, G
    MILSTEIN, C
    [J]. NATURE, 1975, 256 (5517) : 495 - 497
123